Comparison of Peripherally Acting Substance for Treatment of Detrusor Overactivity: What is New; What is in the Pipeline?

EAU Update Series Pub Date : 2004-12-01 Epub Date: 2004-10-19 DOI:10.1016/j.euus.2004.09.001

Andrea Tubaro, Cosimo De Nunzio

{"title":"Comparison of Peripherally Acting Substance for Treatment of Detrusor Overactivity: What is New; What is in the Pipeline?","authors":"Andrea Tubaro, Cosimo De Nunzio","doi":"10.1016/j.euus.2004.09.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective:</h3><p>Overactive bladder is an highly prevalent syndrome involving up to 17% of the population in both western Europe and US and is often associated with detrusor overactivity. Significant improvement in the management of this condition has recently occurred cause the availability of new drugs.</p></div><div><h3>Methods:</h3><p>The Medline database has been extensively searched. Research has also involved industrial and private databases available online and specialised in the development of new drugs.</p></div><div><h3>Results:</h3><p>Antimuscarinics remain the gold standard in the management of detrusor overactivity although the condition mostly goes undiagnosed in non neurogenic patients suffering from overactive bladder syndrome. A number of receptors other than muscarinics have been investigated as possible new targets although no novel effective drugs have been yet developed.</p></div><div><h3>Conclusion:</h3><p>Antimuscarinic drugs dominate medical treatment of symptoms and signs associated with detrusor overactivity although new drugs will hopefully be available in the future based on alternative pathophysiological mechanism.</p></div>","PeriodicalId":100385,"journal":{"name":"EAU Update Series","volume":"2 4","pages":"Pages 161-169"},"PeriodicalIF":0.0000,"publicationDate":"2004-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.euus.2004.09.001","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EAU Update Series","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1570912404000443","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2004/10/19 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 12

Abstract

Objective:

Overactive bladder is an highly prevalent syndrome involving up to 17% of the population in both western Europe and US and is often associated with detrusor overactivity. Significant improvement in the management of this condition has recently occurred cause the availability of new drugs.

Methods:

The Medline database has been extensively searched. Research has also involved industrial and private databases available online and specialised in the development of new drugs.

Results:

Antimuscarinics remain the gold standard in the management of detrusor overactivity although the condition mostly goes undiagnosed in non neurogenic patients suffering from overactive bladder syndrome. A number of receptors other than muscarinics have been investigated as possible new targets although no novel effective drugs have been yet developed.

Conclusion:

Antimuscarinic drugs dominate medical treatment of symptoms and signs associated with detrusor overactivity although new drugs will hopefully be available in the future based on alternative pathophysiological mechanism.

查看原文本刊更多论文

外周作用物质治疗逼尿肌过度活动的比较:新进展正在进行的工作是什么?

目的:膀胱过度活动是一种非常普遍的综合征，涉及西欧和美国人口的17%，通常与逼尿肌过度活动有关。由于新药物的可用性，这种情况的管理最近发生了重大改善。方法:广泛检索Medline数据库。研究还涉及在线提供的工业和私人数据库，以及专门开发新药的数据库。结果:抗尿毒素仍是治疗逼尿肌过度活动的金标准，尽管这种疾病在非神经源性膀胱过度活动综合征患者中大多未被诊断出来。除毒蕈素外，许多受体已被研究作为可能的新靶点，但尚未开发出新的有效药物。结论:抗毒蕈碱类药物在逼尿肌过度活动相关症状和体征的治疗中占主导地位，但基于其他病理生理机制，未来有望开发出新的药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EAU Update Series

自引率

0.00%

发文量